Who's online

There are currently 0 users and 26 guests online.

CURRICULUM VITAE MOSIALOS GEORGIOS


Member: 

I. Personal information
Name : Mosialos George
Title : Professor
Tel /Fax: +30-2310998907
Email:    gmosialo@bio.auth.gr

Ι.1 Academic qualifications:
1986 B.Sc.    Aristotle University of Thessaloniki (Chemistry)
1993 Ph.D.    Boston University (Chemistry/Biochemistry)

I.2 Experience:
1987-1990    Teaching Assistant, Chemistry Dept., Boston University, Boston, MA
1989-1992    Research Assistant, Biology Dept., Boston University, Boston, MA
1992-1994    Research Fellow, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
1994-1998    Instructor, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
1999            Assistant Professor, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
1999-2004    Group Leader grade B, Biomedical Sciences Research Center “Al. Fleming”, Institute of Immunology, Vari, Greece
2004-2010    Group Leader grade A/Associate Researcher, Biomedical Sciences Research Center “Al. Fleming”, Institute of Immunology, Vari, Greece
2005-2012    Associate Professor, Schooll  of Biology, Artistotle University of Thessaloniki
2012-present Professor, School of Biology, Aristotle University of Thessaloniki

Ι.3 Research Interests:
1.Molecular mechanisms of oncogenesis by Epstein-Barr virus
2.Regulation of the transcription factor NF-kappaB in health and disease

ΙΙ. Teaching responsibilities
Undegraduate and graduate courses

ΙΙ.1. Undergraduate studies
    ΙΙ.1.1. Biology Department
    Α. Taught modules:
Biochemistry
Special topics in Molecular Biology
Biotechnology of Animals and Plants

Β. Training
Supervision of 2 senior theses and 2 practical exercises per year

ΙΙ.2. Postgraduate studies
    ΙΙ.2.1. Biology department
    Α. Taught modules:
AUTH SCHOOL OF BIOLOGY MSc PROGRAM
Applied genetics and biotechnology
G1. Genome structure and organizationj
G5. Genetic engineering
G7. Applications of genetics and biotechnology in the improvement of animal and plant organisms 

Β. Dissertations
Supervision of 2 MSc theses

 
ΙΙI. Supervision of Postgraduate Students (PhD)
Supervision of 6 completed and 3 in progress PhD theses

ΙV. R&D Competitive Research Projects
Participation in 6 National and 7 International research projects

V. Participation in educational programs

VΙ. Participation in conferences

VII. ADMINISTRATION EXPERIENCE
Member of the AUTH School of Biology Convection  (2006-2013)
Member of the “Organization and Operation” committee of the AUTH School of Biology (2007-2011)
Member of the “Research Strategy” committee of the AUTH School of Biology (2007-2011)

Member of the FEBS fellowship committee (2008-2013)

Head, Department of Genetics, Developmental and Molecular Biology, School of Biology, AUTH (2011-2012)

Member, Executive Council, School of Biology, AUTH (2011-2012)

VIIΙ. HONORS, SPECIAL RECOGNITION

1994    Leukemia Sociaty of America Fellow

2000    EMBO Young Investigator Award
2003    Bodossaki Foundation Academic Prize in Molecular Biomedicine

2009    Leukemia and Lymphoma Society of America Scholar

Α. Journals Editor
PLoS ONE

 

TheScientificWorldJOURNAL

Β. REVIEWER FOR JOURNALS

  • American Journal of Pathology

  • Biochimica and Biophysica Acta

  • Biochemical Journal

  • Blood

  • British Journal of Dermatology

  • Carcinogenesis

  • EMBO Journal

  • FEBS letters

  • Journal of Biological Chemistry

  • Journal of Clinical Virology

  • Journal of Experimental Medicine

  • Journal of General Virology

  • Journal of Virology

  • Molecular and Cellular Biology

  • Molecular Cancer

  • Oncogene

  • PLoS Biology

  • PLoS ONE

  • Proceedings of the National Academy of Sciences, USA

  • Trends in Cell Biology

  • Trends in Immunology

  • Virology 

C. Organized Conferences and Workshops
Co-organizer

 

Molecular Mechanisms in Signal Transduction and Cancer, FEBS Advanced lecture course, Spetses, Greece, 2005

 

 

Molecular Mechanisms in Signal Transduction and Cancer, FEBS-EMBO Advanced lecture course, Spetses, Greece, 2007

 

 

 

 

Molecular Mechanisms in Signal Transduction and Cancer, FEBS-EACR Advanced lecture course, Spetses, Greece, 2009

 

 

 

 

Molecular Mechanisms in Signal Transduction and Cancer, EACR-FEBS Advanced lecture course, Spetses, Greece, 2011

 

 

 

Molecular Mechanisms in Signal Transduction and Cancer, FEBS Advanced lecture course, Spetses, Greece, 2013

D. AWARDS AND GRANTS
  
1996-2000    United States National Cancer Institute R29 grant award
2000-2001    Hellenic Secretariat of Research and Technology ΠΕΝΕΔ 99 grant
2000-2006    Howard Hughes Medical Institute International Scholarship Award in Infectious Diseases and Parasitology
2001-2004    Human Frontiers Science Program Grant
2003-2006    PΜ External Research Program Grant
                

2004-2009    RIGHT-European Comission Integrated Project
2006-2008    Two Hellenic Secretariat of Research and Technology ΠΕΝΕΔ 2003 grants
2006-2010    INCA-European Comission Integrated Project
2010-2013    Hellenic Secretariat for Research and Technology, Program HERACLEITUS-II

2011-2015    HPV-AHEAD-European Comission

2011-2015    THALES-MIS379465 Hellenic Ministry of Education and Religious Affairs

2012-2015    ARISTEIA-1921-EMBRACE, Hellenic Secretariat for Research and Technology

Ε. Selected Invited Seminars
1. Mosialos G. TRAFs in NF-kappaB activation by the Epstein-Barr virus transforming gene LMP1.  Annual Meeting of the American Association of Immunologists, New Orleans, Louisiana, USA, 1996.

2. Mosialos G. Molecular mechanisms of action of the transforming protein LMP1. Annual meeting of the Hellenic Society of Biochemistry and Molecular Biology, Glyfada, Greece, 1999 [Plenary lecture].

3. Mosialos G. Epstein-Barr virus and viral carcinogenesis. 6th Panhellenic Virology Conference, Athens, 2001 [Plenary Lecture].

4. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G. Regulation of NF-κB activity by the cylindromatosis tumor suppressor gene product. Keystone Symposia 2004, Snowbird, Utah, USA, 2004.

5. Trompouki E, Kontoyiannis D, and Mosialos G. Targeted inactivation of the cyl;indromatosis tumor suppressor gene causes perinatal lethality in mice. Keystone Symposia 2006, Fairmont Banff Springs, Banff, Alberta, Canada 2006.

6. Mosialos G. The complex regulation of transcription factor NF-κB in health and disease. 2nd Bioscience Conference of the University of Patras, Patras, Greece, 2007.

7. Mosialos G, Trompouki E, Tsagaratou A, and Kontoyiannis D. Functional characterization of the cylindromatosis tumor suppressor. 32nd FEBS Congress,Vienna, Austria, 2007.

8. Mosialos G. Functional characterization of the cylindromatosis tumor supressor in model organisms. University Medical Centre of the University of Mainz Seminar Series, Mainz, Germany, December 20th, 2007.

9. Mosialos G. Functional characterization of the cylindromatosis tumor suppressor. 30th Scientific Conference of Hellenic Association for Biological Sciences, Thessaloniki, May 22-24, 2008.

10. Mosialos G. Exploring the multiple talents of the cylindromatosis tumor suppressor. Department of Biological Sciences Seminar Series, University of Cyprus, Nicosia, Cyprus, April 16th, 2010.

11. Mosialos G. Regulation of cellular homeostasis by the cylindromatosis tumor suppressor. 64ο Annual Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Athens, 2013.

F. Membership - National Council

IX. SOCIAL ACTIVITY
Scientific Presentations in Open University of the Municipality of Thessaloniki.

X. MEMBER OF SCIENTIFIC/EDUCATIONAL SOCIETIES
Hellenic Society of Biochemistry and Molecular Biology
Hellenic Society of Biological Sciences
American Society for Microbiology

XI. PUBLICATIONS

Α. PhD Thesis
1. Mosialos G.  Mutational analysis of a conserved consensus phosphorylation site in the retroviral oncoprotein vRel and in chicken cRel.  Ph.D. thesis, Boston University, Boston, 1993.

B. Publications - Journals & Periodicals
1.  Yupsanis T, Mosialos G, Georgatsos JG.  Redundancy of a chromatin-associated nuclease in a wheat-rye hybrid.  Biochimie und Physiologie der Pflanzen 184:179-182, 1989.
2.  Delwart EL, Mosialos G, Gilmore TD.  Retroviral envelope glycoproteins contain “Leucine Zipper:-like repeat.  AIDS Research and Human Retroviruses 6:703-706, 1990.
3.  Kamens J, Richardson P, Mosialos G, Brent R, Gilmore TD.  Oncogenic transformation by vRel requires an amino-terminal activation domain.  Mol. Cell. Biol. 10:2840-2847, 1990.
4.  Mosialos G, Hamer P, Capobianco AJ, Laursen RA, Gilmore TD.  A conserved protein kinase-A recognition sequence is structurally linked to transformation by p59v-rel and cytoplasmic retention of p68c-rel.  Mol. Cell. Biol. 11:5867-5877, 1991.
5.  Capobianco AJ, Chang D, Mosialos G, Gilmore TD.  p105, the NF-?B p50 precursor, is one of the cellular proteins complexed with the vRel oncoprotein in transformed chicken spleen cells.  J. Virol. 66:3758-3767, 1992.
6.  Mosialos G, Gilmore TD.  vRel and cRel are differentially affected by mutations at a conserved protein kinase recognition sequence.  Oncogene 8:721-730, 1993.
7.  Mosialos G, Hanissian S, Jawahar S, Vara L, Kieff E, Chatalia T.  A Ca++/Calmodulin-dependent protein kinase-Gr, expressed after transformation of primary B lymphocytes by Epstein-Barr virus (EBV) is induced by the EBV oncogene LMP1.  J. Virol. 68:1697-1705, 1994.
8.  Feinstein R, Bolton WK, Quinones JN, Mosialos G, Sif S, Huff JL, Capobianco AJ, Gilmore TD.  Characterization of a chicken cDNA encoding the retinoblastoma gene product.  Biochim. Biophys. Acta 1218:82-86, 1994.
9.  Yalamanchili R, Tong X, Grossman S, Johannsen E, Mosialos G, Kieff E.  Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV.  Virology 204:634-641, 1994.
10.  Mosialos G, Yamashiro S, Baughman R, Matsudaira, P, Vara L, Matsumura F, Kieff E, Birkenbach M.  Epstein-Barr virus infection induces expression in B lymphocytes of a novel gene encoding an evolutionarily conserved 55-kD actin-bundling protein. J. Virol. 68:7320-7328, 1994.
11.  Johannsen E, Koh E, Mosialos G, Tong X, Kieff. E, Grossman E.  Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by Jk and PU.1.  J. Virol. 69:253-262, 1995.
12.  Kaye K, Izumi K, Mosialos G, Kieff E.  The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B lymphocyte transformation; fibroblast co-cultivation complements a critical function within the terminal 155 residues.  J. Virol. 69:675-683, 1995.
13.  Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family.  Cell, 80:389-399, 1995.
14.  Tong X, Drapkin R, Yalamanchili R, Mosialos G, Kieff E. The Epstein-Barr virus nuclear protein 2 acidic domain interacts with a novel cellular coactivator that can associate with TFIIE. Mol. Cell. Biol., 15:4735-4744, 1995.
15.  Mosialos G, Birkenbach M, Ayehunie S, Matsumura F, Pinkus GS, Kieff E, Langhoff E.  Circulating human dendritic cells differentially express high levels of a 55-kD actin-bundling protein.  Am. J. Pathology 148:593-600, 1996.
16.  Devergne O, Hatzivasilliou E, Izumi K, Kaye K, Kleijnen M, Kieff E, Mosialos G. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF- kappaB activation.  Mol. Cell. Biol. 16:7098-7108,1996.
17.  Kaye K, Devergne O, Harada J, Izumi K, Yalamanchili R, Kieff E, Mosialos G.  TNF Receptor Associated Factor 2 (TRAF2) is a mediator of NF-?B Activation by the Epstein-Barr Virus Transforming Protein LMP1.  Proc. Natl. Acad. Sci., USA 93:11085-11090, 1996.
18.  Ishida T, Mizushima S, Azuma S, Kobayshi N, Tojo T, Suzuki K, Aizawa, S, Watanabe T, Mosialos G, Kieff E, Yamamoto T, Inoue J.  Identification of TRAF6, a novel TRAF protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region.  J. Biol. Chem. 271:28745-28748, 1996.
19.  Eliopoulos A, Dawson C, Mosialos G, Floettmann J, Rowe M, Armitage R, Dawson J, Kerr D, Wakelman M, Reed J, Kieff E, Young L.  CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: Involvement of TRAF3 as a common mediator.  Oncogene 13: 2243-2254, 1996.
20.  Mosialos G.  The role of Rel/NF-kB proteins in viral oncogenesis and the regulation of viral transcription.  Seminars in Cancer Biology, 8:121-129, 1997
21.  Mosialos  G.  Signal transduction by the epstein-barr virus latent membraneprotein-1.  EBV Report, 4:121-126, 1997.
22.  Miller W, Mosialos G, Kieff E, Raab-Traub N.  Epstein-Barr Virus LMP1 induction of the Epidermal Growth Factor Receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB.  J. Virol. 71:586-594, 1997.
23.  VanArsdale T, VanArsdale S, Force W, Walter B, Mosialos G, Kieff E, Reed J, Ware C.  Lymphotoxin-beta Receptor signaling complex: the role of TRAF3 recruitment in cell death and activation of Nuclear Factor-kappaB. Proc. Natl. Acad. Sci., USA 94:2460-2465, 1997.
24.  Pinkus GS, Pinkus JI, Langhoff E, Matsumura F, Yamashiro S, Mosialos G, Said JW.  Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin’s Disease.  Evidence for a dendritic or B cell derivation?  Am. J. Pathol. 150:543-562, 1997.
25.  Chatila T, Ho N, Liu P, Liu S, Mosialos G, Kieff E, Speck S.  The Epstein-Barr Virus induced Ca2+/Calmodulin dependent kinase type IV/GR promotes a Ca+2 dependent switch from latency to viral replication.  J. Virol. 71:6560-6567, 1997.
26.  Hatzivassiliou E, Miller W, Raab-Traub N, Kieff E, Mosialos G.  A fusion of the Epstein-Barr virus latent membrane protein 1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation  of epidermal growth factor receptor expression, nuclear factor kappaB, and stress activated protein kinase.  J. Immunol. 160:1116-1121, 1998.
27.  Sylla BS, Hung SC, Davidson D, Hatzivassiliou E, Malinin N, Wallach D, Gilmore TD, Kieff E, Mosialos G.  Epstein-Barr virus transforming protein latent infection membrane protein 1 activates transcription factor NF-?B through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKK? and IKK?.  Proc. Natl. Acad. Sci., USA 95:10106-10111, 1998.
28.  Devergne O, McFarland EC, Mosialos G, Izumi KM, Ware CF, Kieff E.  Role of the the TRAF binding site and NF-kB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J. Virol. 72:7900-7908, 1998.
29. Cahir McFarland ED, Izumi KM, Mosialos G. Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene 18:6959-6964, 1999.
30. Sylla BS, Murphy K, Cahir-McFarland E, Lane WS, Mosialos G, Kieff E. The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-kappa B. Proc. Natl. Acad. Sci. USA 97:7470-7475, 2000.
31. Mosialos G. Cytokine signaling and Epstein-Barr virus-mediated cell transformation. Cytokine and growth factor reviews 12:259-270, 2001.
32. Ishii T, Kwon H, Hiscott J, Mosialos G, Koromilas AE. Activation of the IkappaBalpha kinase (IKK) complex by double-stranded RNA-binding defective and catalytic inactive mutants of the interferon-inducible protein kinase PKR. Oncogene 20:1900-1912, 2001.
33. Luftig MA, Cahir-McFarland E, Mosialos G, Kieff ED. Effects of the NIK aly mutation on NF-{kappa}B activation by the Epstein-Barr virus latent infection membrane protein, LT{beta}R, and CD40. J. Biol. Chem. 276:14602-14606, 2001.
34. Hatzivassiliou E, Mosialos G. Cellular signalling pathways engaged by the Epstein-Barr virus transforming protein LMP1. Frontiers in Bioscience, 7:319-329, 2002.
35. Prokova V, Mosialos G, Kardassis D. Inhibition of transforming growth factor beta signaling and Smad-dependent activation of transcription by the latent membrane protein 1 of Epstein-Barr virus. J. Biol. Chem. 277:9342-9350, 2002.
36. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424:793-796, 2003.
37. Luftig M, Prinarakis E, Yasui T, Tsichritzis T, Cahir-McFarland E, Inoue JI, Nakano H, Mak TW, Yeh WC, Li X, Akira S, Suzuki N, Suzuki S, Mosialos G, Kieff E. Epstein-Barr Virus Latent Membrane Protein 1 Activation of NF-kappaB Through IRAK1 and TRAF6. Proc. Natl. Acad. Sci. USA 100:15595-15600, 2003.
38. Jono H, Lim JH, Chen LF, Xu H, Trompouki E, Pan ZK, Mosialos G, Li JD. NF-kappaB Is Essential for Induction of CYLD, the Negative Regulator of NF-kappaB: Evidence for A Novel Inducible Auto-Regulatory Feedback Pathway. J. Biol. Chem., 279:36171-36174, 2004.
39. Panagopoulos D, Victoratos P, Alexiou M, Kollias G, Mosialos G. Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo. J. Virol., 78:13253-13261, 2004.
40. Hatzivassiliou E, Tsichritzis T, Mosialos G. Induction of apoptosis by rewiring the signal transduction of the Epstein-Barr virus oncoprotein LMP1 towards caspase activation. J. Virol., 79:5215-5219, 2005.
41. Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M, Sif S.  The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol. 25:7953-7965, 2005.
42. Tzimas C, Michailidou G, Arsenakis M, Kieff E, Mosialos G, Hatzivassiliou
EG.  Human ubiquitin specific protease 31 is a deubiquitinating enzyme implicated in activation of nuclear factor-kappaB. Cell Signal. 18:83-92, 2006.
43. Hatzivassiliou EG, Kieff E, Mosialos G.  Constitutive CD40 signaling phenocopies the transforming function of the Epstein-Barr virus oncoprotein LMP1 in vitro. Leuk Res. 31(3):315-320, 2007.
44. Tsichritzis T, Gaentzsch PC, Kosmidis S, Brown AE, Skoulakis EM, Ligoxygakis P, Mosialos G. A Drosophila ortholog of the human cylindromatosis tumor suppressor gene regulates triglyceride content and antibacterial defense. Development 134(14):2605-2614, 2007.
45. Demetriades C, Mosialos G. The LMP1 promoter can be transactivated by NF-kappaB directly. J. Virol., 83(10):5269-5277, 2009.
46. Trompouki E, Tsagaratou A, Kosmidis S, Dolle P, Qian J, Kontoyiannis DL, Cardoso W, Mosialos G. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia, 11(5):469-476, 2009
47. Tsagaratou A, Trompouki E, Grammenoudi S, Kontoyiannis DL, Mosialos G. Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NEMO-dependent manner. J. Immunol., 185(4):2032-2043, 2010.

48. Chantzoura E, Prinarakis E, Panagopoulos D, Mosialos G, Spyrou G. Glutaredoxin-1 regulates TRAF6 activation and the IL-1 receptor/TLR4 signalling. Biochem Biophys Res Commun., 403(3-4):335-339, 2010.

 

49. Tsagaratou A, Kontoyiannis DL, Mosialos G. Truncation of the deubiquitinating  domain of CYLD in myelomonocytic cells attenuates inflammatory responses. PLoS One., 6(1):e16397, 2011. 
50.  Megas C, Hatzivassiliou EG, Yin Q, Marinopoulou E, Hadweh P, Vignali DA, Mosialos G. Mutational analysis of TRAF6 reveals a conserved functional role of the RING dimerization interface and a potentially necessary but insufficient role of RING-dependent TRAF6 polyubiquitination towards NF-κB activation. Cell Signal., 23(5):772-777, 2011.
51. Tsagaratou A, Grammenoudi S, Mosialos G. Differential requirement of IKKβ for CYLD-dependent representation of thymic and peripheral T cell populations. Eur. J. Immunol., 41(10) 3054-3062, 2011 .

52. Antonaki A, Demetriades C, Polyzos A, Vatsellas G, Lavigne M, Banos A, Apostolou E, Mantouvalou E, Papadopoulou D, Mosialos G, Thanos D. Genomic analysis reveals a novle NF-κΒ binding site in Alu repetitive elements. J. Biol. Chem.,  286(44):38768-38782, 2011.

53. Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I. Inactivation of the Deubiquitinase CYLD in Hepatocytes Causes Apoptosis, inflammation, Fibrosis, and Cancer. Cancer Cell, 21:738-750, 2012.

54 Yasui T, Sakakibara-Yada K, Nishimura T, Morita K, Tada S, Mosialos G, Kieff E, Kikutani H. Protein kinase N1, a cell inhibitor of Akt kinase, has a central role in quality control of germinal center formation. Proc. Natl Acad Sci USA. 109(51):21022-21027, 2012. 

C. Conference Papers
1.  Richardson P, Mosialos G, Kamens J, Brent R and Gilmore TD.  Transcriptional activation by Rel and Dorsal proteins [poster].  Fifth Annual Meeting on Oncogenes, Frederick, Maryland, USA, 1989.
2.  Richardson P, Mosialos G, Kamens J, Brent R and Gilmore TD.  Transformation by Rel proteins correlates with gene activation in yeast [poster].  AACR Special Meeting on Steroid Receptors, Transcription Factors and Gene Expression, San Diego, California, USA, 1990.
3.  Mosialos G, Richardson P, Hamer P and Gilmore TD. Mutational analysis of a conserved consensus site for phosphorylation by protein kinase A in Rel proteins [ poster].  Seventh Annual Meeting on Oncogenes, Frederick, Maryland, USA, 1991.
4.  Mosialos G and Gilmore TD.  Mutations in a conserved protein kinase-A recognition site differentially affect binding by vRel and cRel to ?B sites [Lecture].  Eighth Annual Meeting on Oncogenes, Frederick, Maryland, USA, 1992.
5.  Mosialos G, Hanissian SH, Jawahar S, Vara L, Kieff E, and Chatila TA.  The Epstein-Barr virus oncogene LMP1 induces CaM kinase-Gr in human B lymphocytes [poster].  1994 Keystone Symposia: Human Tumor Viruses, Taos, New Mexico, USA, 1994.
 6.  Mosialos G and Kieff E.  Identification of cellular proteins that interact with the carboxy-terminal region of LMP1 [Lecture].  Cold Spring Harbor Laboratory Meeting: Cancer Cells: Epstein-Barr Virus & Associated Diseases, Cold Spring Harbor, New York, USA, 1994.
7.  VanArsdale T, Walter B, VanArsdale S, Xhu M, Lai MC, Mosialos G, Kieff E, Ware C.  TNF and Lymphotoxin beta receptor signaling complexes are targeted by Epstein-Barr virus [poster].  The 9th International Congress of Immunology, San Francisco, California, USA, 1995.
8.  Devergne O, Hatzivassiliou E, Kaye K, Izumi K, Gruss HJ, Kieff E, Franken M, Wang F, Harada J and Mosialos G.  TNFR associated factors (TRAFs) 1 and 2 mediate NF-?B activation by the EBV transforming protein LMP1 [Lecture]. European Cytokine Network 7:196, 1996.
9.  Force WR, Williams-Abbott L, Mosialos G, Kieff E, Nakano H and Ware CF.  LT?R interacts with multiple TRAFs: Signaling specificity in the activation of NF-?B [poster].  European Cytokine Network 7:207, 1996.
10.  Kieff E, Mosialos G, Robertson E, Devergne O, Izumi K, Kaye K, Yalamanchili R, Harada S, Lin J, Hatzivassiliou E and Harada J.  Signal transduction and transcriptional regulation in Epstein-Barr virus transformation of primary human B lymphocytes [Lecture].  21st Herpesvirus Workshop, Northern Illinois University, DeKalb, Illinois, USA, 1996.
11.  Force WR, Williams-Abbott LJ, Mosialos G, Kieff E and Ware CF.  Lymphotoxin beta receptor signals NF-kappaB and binds TRAF3 [poster].  Annual Meeting of the American Association of Immunologists, New Orleans, Louisiana, USA, 1996.
12. Mosialos G. TRAFs in NF-?B activation by the Epstein-Barr virus transforming gene LMP1 [Lecture].  Annual Meeting of the American Association of Immunologists, New Orleans, Louisiana, USA, 1996.
13.  Izumi K, Harada S, Lin J, Sylla B, Mosialos G, Devergne O, Kaye K, McFarland E, Kieff E.  Epstein-Barr virus usurps control of Tumor Necrosis Factor Receptor and Notch pathways to transform human B lymphocytes [Lecture].  Cellular targets of viral oncogenesis (American Association for Cancer Research special conference in cancer research), Dana Point, California 1998.
14. Mosialos G. Molecular mechanisms of action of the transforming protein LMP1 [Lecture]. Annual meeting of the Hellenic Association of Biochemistry and Molecular Biology, Glyfada, Greece, 1999  [Plenary Lecture].
15. Hatzivassiliou E, Tzimas C, Mihailidou Y, Arsenakis M, Kieff E and Mosialos G.  Characterization of a novel homolog of deubiquitinating enzymes that associates with tumor necrosis factor receptor associated factor 2 (TRAF2) [poster]. European Life Sciences Organization 2000 meeting, Geneva, Switzerland, 2000.
16. Mosialos G. Epstein-Barr virus and viral carcinogenesis [Διάλεξη]. 6th Panhellenic Virology Conference, Athens, 2001 [Plenary Lecture].
17. Hatzivassiliou E, Tzimas C, Kieff E, and Mosialos G. Characterization of a novel homolog of deubiquitinases impicated in latent membrane protein 1 signaling [Lacture]. Howard Hughes Medical Institute 2001 meeting of international Research Scholars, Vancouver, Canada, 2001.
18. Trompouki E and Mosialos G. A candidate tumor suppressor gene product that functions as a deubiquitinating enzyme is involved in signal transduction by the Epstein-Barr virus transforming protein LMP1 [Lecture]. Howard Hughes Medical Institute 2002 meeting of international Research Scholars, Palm Cove, Australia, 2002.
19. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G. Regulation of NF-κB activity by the cylindromatosis tumor suppressor gene product [Lecture]. Keystone Symposia 2004, Snowbird, Utah, USA, 2004.
20. Trompouki E, Tsagaratou A, Kontoyiannis D and Mosialos G. Inactivation of the murine cyld gene causes perinatal lethality [Lecture]. Annual meeting of the Hellenic Association of Biochemistry and Molecular Biology, Athens, Greece, 2005.
21. Demetriades C, Antonaki A, Apostolou E, Vatsellas G, Papadopoulou D, Agelopoulos M. Mosialow G and Thanos D. Identification of direct NF-κB target genes in models of virus infection [Lecture]. Annual meeting of the Hellenic Association of Biochemistry and Molecular Biology, Athens, Greece, 2005.
22. Trompouki E, Kontoyiannis D, and Mosialos G. Targeted inactivation of the cyl;indromatosis tumor suppressor gene causes perinatal lethality in mice [Lacture]. Keystone Symposia 2006, Fairmont Banff Springs, Banff, Alberta, Canada 2006.
23. Demetriades C and Mosialos G. NF-κB regulates directly the Epstein-Barr Virus LMP1 promoter [Lecture]. Annual meeting of the Hellenic Association of Biochemistry and Molecular Biology, Patras, Greece, 2006.
24. Apostolou E, Antronaki A, Demetriades C, Agelopoulos M, Gagos S, Mosialos G, and Thanos D. NF-κB targeting in the human genome [Lecture]. Annual meeting of the Hellenic Association of Biochemistry and Molecular Biology, Patras, Greece, 2006.
25. Mosialos G. The complex regulation of transcription factor NF-κB in health and disease [Lecture]. 2nd Bioscience Conference of the University of Patras, Patras, Greece, 2007.
26. Mosialos G, Trompouki E, Tsagaratou A, and Kontoyiannis D. Functional characterization of the cylindromatosis tumor suppressor [Lecture]. 32nd FEBS Congress,Vienna, Austria, 2007.
27. Tsagaratou A, Trompouki E, Kontoyiannis D and Mosialos G. CYLD: A key molecule in T cell development [Lecture]. EMBO/ ENII conference, Sardinia, Italy, 2007.
28. Tsagaratou A, Trompouki E, Kontoyiannis D and Mosialos G. The cylindromatosis tumor supressor (CYLD) is a key molecule in T cell development, activation and homeostasis [poster]. 33rd FEBS Congress, Athens, Greece, 2008.
29. Hatzivassiliou EG and Mosialos G. The regulatory subunit PP4R1 of protein phosphatase PP4 is implicated in activation of NF-kappaB by the Epstein-Barr virus oncoprotein LMP1 [poster]. 34th FEBS Congress, Prague, Czech Republic, 2009.
30. Hadweh P, Hatzivassiliou E, Mavromatidis V, Mosialos G. Signal transduction pathways that play a critical role in the survival of Epstein-Barr virus-transformed human B lymphocytes [Lecture]. “New Frontiers in Infection-related Cancer”-INCA Public Workshop, Veyrier-du-lac, France, 2010.

31. Hatzivassiliou E, Hadweh P, Mosialos G. Molecular and functional characterization of the role of TRAF3 in Epstein-Barr virus mediated cellular transformation [poster]. 14th Biennial Conference of the International Association for Research on Epstein-Barr & Associated Diseases, Birmingham, UK, 2010.

32. Nikolaou K, Mosialos G, Talianidis I. The role of CYLD in liver [Lecture]. 61ο Annual Meeting of teh Hellenic Society of Biochemistry and Molecular Biology, Alexandroupolis, Greece 2010.

33. Mavromatidis V, Karanastasi S, Mosialos G. Identification of kinase inhibitors that affect negatively the viability of Epstein-Barr virus transformed B lymphocytes [Lecture]. 61ο Annual Meeting of the Hellenic Socisty of Biochemistry and Molecular Biology, Alexandroupolis, Greece, 2010.

34. Ravanidis S, Polyzoidou E, Lourbopoulos A, Lagoudaki R, Poulatsidou K, Tascos N, Mosialos G, Arsenakis M, Grigoriadis N. Neural precursor cells improve clinical outcome of experimental autoimmune encephalomyelitis via reduced chemotaxis of peripheral lymphocytes [poster]. 20th Meeting of the European-Neurological-Society, Berlin, Germany, 2010.

35. Hadweh PM, Mosialos G. Evaluation of the role of TRAFs in B lymphocyte transformation by Epstein-Barr virus [Παρουσίαση poster]. Molecular mechanisms in signal transduction and cancer-EACR-FEBS Advanced Lecture Course, Spetses, Greece, 2011.

36. Kefalopoulou S.1, Mosialos G.1 and Hatzivassiliou E.2 Modulation of dexamethasone-dependent transcription by the Epstein-Barr virus oncoprotein LMP1 signaling pathway [Poster]. 63ο Annual Meeting of the Hellenic Society of Biochemistry and Molecular Biology, Heraklion, Greece, 2012.

37. Polyzos A, Nikolaou K, Talianidis I, Mosialos G. Inactivation of CYLD in murine hepatocytes is associated with downregulation of the majority of liver signature genes and deregulation of gene expression associated with immune regulation apoptosis and cell cycle [Poster]. EMBO Workshop on Liver and Pancreas Development, Function and Disease. Cape Sounio, Athens, Greece, 2013

D. Publications - Academic Educational Books

E.  Publications in Books & Book chapters
1. Gilmore TD and Mosialos G. 2003. Viruses as intruders in the Rel/NF-kB signalling pathway.  In, Nuclear Factor-?B: Regulation and Role in Disease (ed. R Beyaert), Kluwer Academic Publishers, The Netherlands, pp 91-115.

F. Publications EDUCATIONAL MATERIAL